Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Bausch + Lomb Launches Ovd in the U.S.
Bausch + Lomb Corporation has recently launched the StableVisc™ cohesive ophthalmic viscosurgical device (OVD) and the TotalVisc™ Viscoelastic System in the United States. These new products offer eye surgeons dual-action protection during cataract surgery, expanding the range of options available.…
Haag-Streit Launches New EyeSuite Software
Haag-Streit has recently launched EyeSuite software version i9.13, which comes with new features for the Anterior Chamber Suite of the Eyestar 900, as well as market-first functionality for the Lenstar Myopia. Furthermore, Haag-Streit has made additional improvements to its existing…
Ocumension Submits NDA for Zerviate in China
Nicox SA announced that its exclusive Chinese partner, Ocumension Therapeutics, has submitted a new drug application (NDA) seeking approval for commercialization of Zerviate (cetirizine ophthalmic solution), 0.24%, in China. The intended use of Zerviate is for the treatment of ocular…
Tepezza Improves Proptosis in Patients With Chronic TED
Horizon Therapeutics has announced positive and statistically significant topline results from its randomized, double-masked, placebo-controlled Phase 4 clinical trial evaluating TEPEZZA for the treatment of adults with chronic thyroid eye disease (TED) and low CAS, a measure of disease activity.…
Ultomiris Poised for EU Approval as NMOSD Treatment
AstraZeneca’s Ultomiris (ravulizumab) has received a recommendation for marketing authorization in the European Union (EU) for the treatment of adult patients who are anti-aquaporin-4 (AQP4) antibody positive (Ab+) and have neuromyelitis optica spectrum disorder (NMOSD). If authorized, Ultomiris would become…
New Fish Oil Supplement May Reverse Vision Loss
According to a recent study, scientists may have found a promising treatment for one of the leading causes of blindness worldwide. The study suggests that a new fish oil supplement could hold the key to preventing vision loss caused by…
Eyes May Offer Early Clues to Alzheimer’s Disease
Researchers at Cedars-Sinai have conducted the most comprehensive analysis of retinal changes in Alzheimer’s disease patients and their correlation with brain and cognitive changes. The findings of this study, which have been published in the journal Acta Neuropathologica, are crucial…
Positive Results for Dry AMD Treatment by LumiThera
LumiThera announced the 24-month data from its LIGHTSITE III multicenter clinical trial. The results showed sustained vision improvement in subjects with dry age-related macular degeneration (AMD) who were treated with the Valeda Light Delivery System. LumiThera conducted LIGHTSITE III, a…
Gene Therapy for Retinitis Pigmentosa Shows Promise
People with retinitis pigmentosa typically experience changes in their vision during childhood or early adulthood. The condition commonly results in a decline in both peripheral and night vision, ultimately leading to blindness in the majority of cases. A team of…
Apellis’ Syfovre for Treatment of GA Approved by FDA
The FDA has approved Apellis Pharmaceuticals’ Syfovre (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This marks the first time that patients with GA have an FDA-approved treatment option, which is a significant milestone…